MBX Biosciences Quarterly Balance Sheet
NASDAQ: MBXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
MBX Biosciences financial position
As of Jun 30, 2026, MBX Biosciences reported total assets of $435.9 million, up 88.3% from a year earlier against total liabilities of $26.4 million. Shareholders' equity stood at $409.5 million, or 94.0% of assets. The company held $54.1 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 18.08, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
MBX Biosciences balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 54.12M | 45.21M | 75.29M | 223.13M | 39.78M | 29.90M | 49.35M | 132.87M | — | — | 30.52M | — |
| Short-Term Investments | 364.46M | 394.76M | 298.42M | 168.55M | 185.13M | 210.88M | 212.80M | 144.20M | — | — | 50.15M | — |
| Total Current Assets | 427.86M | 448.54M | 381.54M | 397.50M | 229.19M | 244.28M | 267.29M | 281.17M | — | — | 83.47M | — |
| Property, Plant & Equipment | 4.66M | 3.13M | 2.73M | 2.00M | 1.73M | 1.51M | 1.08M | 1.03M | — | — | 439.00K | — |
| Total Assets | 435.91M | 452.70M | 385.14M | 400.08M | 231.52M | 245.93M | 268.54M | 282.40M | — | — | 84.18M | — |
| Accounts Payable | 4.36M | 6.97M | 2.98M | 3.77M | 5.76M | 4.25M | 5.33M | 5.00M | — | — | 1.39M | — |
| Total Current Liabilities | 23.66M | 14.57M | 15.49M | 12.06M | 11.76M | 10.48M | 11.05M | 10.92M | — | — | 3.93M | — |
| Total Liabilities | 26.37M | 14.95M | 15.92M | 12.54M | 12.28M | 10.50M | 11.09M | 11.03M | — | — | 4.29M | — |
| Shareholders' Equity | 409.54M | 437.76M | 369.22M | 387.54M | 219.24M | 235.42M | 257.44M | 271.37M | -97.89M | -83.05M | -72.47M | -64.82M |
| Retained Earnings | -285.09M | -247.99M | -224.48M | -202.41M | -180.80M | -161.38M | -137.50M | -121.92M | — | — | -75.58M | — |
| Net Cash (Debt) | 418.58M | 439.98M | 373.70M | 391.67M | 224.91M | 240.79M | 262.15M | 277.06M | — | — | 80.68M | — |
| Shares Outstanding | 47.95M | 47.57M | 44.93M | 44.72M | 33.59M | 33.42M | 33.42M | 33.38M | — | — | 1.26M | — |
This table shows 12 quarterly periods of MBX Biosciences's balance sheet, from Q2 2026 back to Q3 2023, across 12 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow MBX's reporting calendar. What is a balance sheet?